| Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double‐blind, randomized, placebo‐controlled phase I studies SA Stoch, S Zajic, J Stone, DL Miller, K Van Dyck, MJ Gutierrez, ... Clinical Pharmacology & Therapeutics 86 (2), 175-182, 2009 | 200 | 2009 |
| Theoretic criteria for antibody penetration into solid tumors and micrometastases GM Thurber, SC Zajic, KD Wittrup Journal of Nuclear Medicine 48 (6), 995-999, 2007 | 170 | 2007 |
| Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model‐based approaches to drug–drug interaction trial design ML Reitman, X Chu, X Cai, J Yabut, R Venkatasubramanian, S Zajic, ... Clinical Pharmacology & Therapeutics 89 (2), 234-242, 2011 | 169 | 2011 |
| Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics–results from single oral dose studies in … SA Stoch, S Zajic, JA Stone, DL Miller, L Van Bortel, KC Lasseter, ... British journal of clinical pharmacology 75 (5), 1240-1254, 2013 | 96 | 2013 |
| Influence of residual water on the adsorption of atmospheric gases in Li− X zeolite: experiment and simulation ND Hutson, SC Zajic, RT Yang Industrial & Engineering Chemistry Research 39 (6), 1775-1780, 2000 | 86 | 2000 |
| Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis JA Stone, JB McCrea, R Witter, S Zajic, SA Stoch British journal of clinical pharmacology 85 (6), 1072-1083, 2019 | 56 | 2019 |
| Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans K Kassahun, I McIntosh, K Koeplinger, L Sun, JE Talaty, DL Miller, ... Drug Metabolism and Disposition 42 (5), 818-827, 2014 | 39 | 2014 |
| Prediction of fully developed turbulent convection with minimal explicit empiricism SW Churchill, SC Zajic AIChE journal 48 (5), 927-940, 2002 | 38 | 2002 |
| Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women MS Anderson, IN Gendrano, C Liu, S Jeffers, C Mahon, A Mehta, ... The Journal of Clinical Endocrinology & Metabolism 99 (2), 552-560, 2014 | 33 | 2014 |
| 298 Final analysis of the phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial … S D’Angelo, G Demetri, B Van Tine, M Druta, J Glod, W Chow, N Pandya, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 21 | 2020 |
| Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma A Gyurdieva, S Zajic, YF Chang, EA Houseman, S Zhong, J Kim, ... Nature communications 13 (1), 5296, 2022 | 19 | 2022 |
| Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs–midazolam and odanacatib EE Marcantonio, J Ballard, CR Gibson, K Kassahun, J Palamanda, ... The Journal of Clinical Pharmacology 54 (11), 1280-1289, 2014 | 18 | 2014 |
| Utility of population pharmacokinetic modeling in the assessment of therapeutic protein‐drug interactions AT Chow, JC Earp, M Gupta, W Hanley, C Hu, DD Wang, S Zajic, M Zhu, ... The Journal of Clinical Pharmacology 54 (5), 593-601, 2014 | 18 | 2014 |
| Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell Personalized Medicine Collaborative SC Zajic, JP Jarvis, P Zhang, KD Rajula, A Brangan, R Brenner, ... Pharmacogenetics and genomics 29 (3), 49-57, 2019 | 16 | 2019 |
| Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS). SP D'Angelo, M Druta, BA Van Tine, DA Liebner, S Schuetze, ... Journal of Clinical Oncology 40 (16_suppl), 11500-11500, 2022 | 13 | 2022 |
| Pharmacokinetic evaluation of darunavir/ritonavir and raltegravir in healthy subjects MS Anderson, V Sekar, F Tomaka, J Mabalot, R Mack, L Lionti, S Zajic, ... 48th Annual ICAAC/46th IDSA meeting, Washington DC, 2008 | 12 | 2008 |
| The absolute bioavailability and effect of food on the pharmacokinetics of odanacatib: a stable-label iv/oral study in healthy postmenopausal women S Zajic, S Rossenu, D Hreniuk, F Kesisoglou, J McCrea, F Liu, L Sun, ... Drug Metabolism and Disposition 44 (9), 1450-1458, 2016 | 11 | 2016 |
| Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment M Akce, A El-Khoueiry, SA Piha-Paul, E Bacque, P Pan, ZY Zhang, ... Cancer chemotherapy and pharmacology 88 (5), 825-836, 2021 | 10 | 2021 |
| Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin. SA Stoch, R Witter, D Hrenuik, C Liu, S Zajic, A Mehta, P Chandler, ... Journal of Population Therapeutics and Clinical Pharmacology= Journal de la …, 2013 | 10 | 2013 |
| Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis. SP D'Angelo, M Druta, BA Van Tine, DA Liebner, S Schuetze, AN Hasan, ... Journal of Clinical Oncology 39 (15_suppl), 11521-11521, 2021 | 9 | 2021 |
Marc ReitmanBranch Chief, NIDDK, NIH在 nih.gov 的电子邮件经过验证
Marc ReitmanBranch Chief, NIDDK, NIH在 nih.gov 的电子邮件经过验证